Clinical Trial for Mesothelioma Patients: Antineoplaston Therapy Program Characteristics

Read the program characteristics for a current clinical trial being conducted to study the effects of Antineoplaston therapy for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Disease Characteristics:
Histologically confirmed stage IV mesothelioma that is unlikely to respond to existing therapy and for which no curative therapy exists
Evidence of disease by CT scan or MRI

Patient Characterizes:
Age:
1 and over
Performance status:
Karnofsky 60-100%
Life expectancy:
At least 2 months
Hematopoietic:
WBC at least 2,000/mm^3
• Platelet count at least 50,000/mm^3
Hepatic:
• Bilirubin no greater than 2.5 mg/dL
• SGOT and SGPT no greater than 5 times upper limit of normal
• Hepatic function adequate
Renal:
• Creatinine no greater than 2.5 mg/dL
• No renal insufficiency
• No history of renal conditions that contraindicate high dosages of sodium
Cardiovascular:
• No uncontrolled hypertension
• No history of congestive heart failure
• No cardiovascular conditions that contraindicate high dosages of sodium
Pulmonary:
• No serious lung disease (e.g., chronic obstructive pulmonary disease)
Other:
• Not pregnant or nursing
• Fertile patients must use effective contraception during and for 4 weeks after study participation
• Not at high medical or psychiatric risk
• No nonmalignant systemic disease
• No active infection

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney